Innovus Pharma Provides Regulatory And Commercial Update On The Label Indication For Zestra® For Female Sexual Desire Disorder ("FSDD") From Health Canada
1/10/2014 9:22:14 AM
LA JOLLA, Calif., Jan. 10, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that its newly acquired wholly-owned subsidiary, Semprae Laboratories, Inc. ("Semprae") is working with Health Canada to finalize the packaging for the indication for its topical over the counter ("OTC") Natural Health Product, Zestra®, for the temporary improved sexual desire in women suffering from female sexual desire disorder" ("FSDD"). The first Canadian Product License approval for this indication was obtained by Semprae in July 2012, but never applied to the Zestra® label. The Company is expected to finalize the new packaging for this product with Health Canada with the approved FSDD indication within 90 days. In addition, the Company is filing to expand the indication to women with Female Sexual Arousal Disorder (FSAD) due to statistically significant improvement in arousal and Female Sexual Function Index (FSFI) scores observed in its large clinical trial in women with FSAD.
Help employers find you! Check out all the jobs and post your resume.
comments powered by